Skip to main content

Table 1 Patient and treatment characteristics (N = 36)

From: Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer

Age, median (years, range)

64 (45–86)

Gender

 Male

20 (55.6)

 Female

16 (44.4)

Location

 Sigmoid colon

21 (58.4)

 Ascending colon

12 (33.3)

 Transverse colon

3 (8.3)

Clinical tumor depth

 T3

13 (36.1)

 T4a

13 (36.1)

 T4b

10 (27.8)

Clinical lymph node metastasis

 N0

1 (2.7)

 N1

16 (44.5)

 N2

19 (52.8)

UICC staging

 IIC

1 (2.7)

 IIIB

15 (41.7)

 IIIC

20 (55.6)

Pretreatment CEA (ng/mL)

 ≦ 5

19 (52.8)

  > 5

17 (47.2)

Ileosotmy/colostomy prior to therapy

 Yes

19 (52.7)

 No

17 (47.3)

Radiotherapy (dose/fractions)

 45 Gy/25

6 (16.7)

 50 Gy/25

25 (69.5)

 50.4Gy/28

4 (11.1)

 46.8Gy/26

1 (2.7)

Post-operative chemotherapy

 FOLFOX

15 (41.7)

 UFUR

11 (30.6)

 Capecitabine

5 (13.9)

 FOLFIRI

2 (5.4)

 None

3 (8.4)

BMI kg/m2 (median) (range)

22.4 (14.8–41.8)

RT-Surgery interval week (median) (range)

11 (6–25)

  1. Data are presented as n (%), unless otherwise indicated
  2. CEA carcinoembryonic antigen, FOLFOX fluorouracil, leucovorin, and oxaliplatin, UFUR Tegafur and Uracil, FOLFIRI fluorouracil, leucovorin, and irinotecan, UICC Union for International Cancer Control, BMI body mass index, RT radiotherapy